false2024Q1Catalent, Inc.6/30FALSEFALSE00015967830.010.011,000,000,0001,000,000,000181,000,000180,000,000180,000,000179,000,0000.010.01100,000,000100,000,00048461,6471,596855353544991461462626180,15724,6973723684,703179,30224,6495383944,7957807,818362362424299212199663333187,90025,0745324275,181REVISIONS OF PREVIOUSLY ISSUED FINANCIAL STATEMENTS
As described in the Amended Fiscal 2022 10-K, in preparing the consolidated financial statements for the three and nine months ended March 31, 2023, the Company identified a $26 million error related to the over-recognition of revenue in the consolidated financial statements it issued with respect to its fiscal year ended June 30, 2022. This error resulted from the misapplication of the contract modification guidance in accordance with ASC 606, Revenue from Contracts with Customers, related to one of the Company’s customer arrangements. The Company assessed the materiality of the error both quantitatively and qualitatively and determined this error to be immaterial to those consolidated financial statements. However, the Company concluded that the effect of correcting the error in the quarter ended March 31, 2023 would materially misstate the Company’s unaudited consolidated financial statements for the three and nine months ended March 31, 2023 and, accordingly, determined that it was necessary to revise the consolidated financial statements it previously issued with respect to the fiscal year ended June 30, 2022.

The following tables reflect the impact of this revision on the Company’s consolidated balance sheet as of June 30, 2022:
Consolidated Balance SheetJune 30, 2022
(Dollars in millions)As Previously
ReportedAdjustmentAs Revised
Prepaid expenses and other$625 $$626 
Total current assets2,916 2,917 
Total assets10,507 10,508 
Other accrued liabilities620 26 646 
Total current liabilities1,072 26 1,098 
Deferred income taxes202 (5)197 
Total liabilities5,712 21 5,733 
Retained earnings538 (20)518 
Total shareholders' equity4,795 (20)4,775 
Total liabilities and shareholders' equity$10,507 $10,508 
62516262,91612,91710,507110,508620266461,072261,09820251975,712215,733538205184,795204,77510,507110,508September 30, 2023
00015967832023-07-012023-09-3000015967832023-10-31xbrli:shares00015967832023-09-30iso4217:USDxbrli:sharesiso4217:USD00015967832022-07-012022-09-300001596783us-gaap:RetainedEarningsMember2023-07-012023-09-300001596783us-gaap:RetainedEarningsMember2022-07-012022-09-300001596783us-gaap:AccumulatedTranslationAdjustmentMember2023-07-012023-09-300001596783ctlt:ACOIAccumulatedGainLossMarketableSecuritiesMember2022-07-012022-09-3000015967832023-06-300001596783us-gaap:CommonStockMember2023-06-300001596783us-gaap:AdditionalPaidInCapitalMember2023-06-300001596783us-gaap:RetainedEarningsMember2023-06-300001596783us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-06-300001596783us-gaap:CommonStockMember2023-07-012023-09-300001596783us-gaap:AdditionalPaidInCapitalMember2023-07-012023-09-300001596783us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-07-012023-09-300001596783us-gaap:CommonStockMember2023-09-300001596783us-gaap:AdditionalPaidInCapitalMember2023-09-300001596783us-gaap:RetainedEarningsMember2023-09-300001596783us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-09-300001596783us-gaap:CommonStockMember2022-06-300001596783us-gaap:AdditionalPaidInCapitalMember2022-06-300001596783us-gaap:RetainedEarningsMember2022-06-300001596783us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-06-3000015967832022-06-300001596783us-gaap:CommonStockMember2022-07-012022-09-300001596783us-gaap:AdditionalPaidInCapitalMember2022-07-012022-09-300001596783us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-07-012022-09-300001596783us-gaap:CommonStockMember2022-09-300001596783us-gaap:AdditionalPaidInCapitalMember2022-09-300001596783us-gaap:RetainedEarningsMember2022-09-300001596783us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-09-3000015967832022-09-300001596783us-gaap:CommonStockMember2023-07-012023-12-310001596783us-gaap:AdditionalPaidInCapitalMember2023-07-012023-12-3100015967832023-07-012023-12-310001596783us-gaap:RetainedEarningsMember2023-07-012023-12-310001596783us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-07-012023-12-310001596783us-gaap:CommonStockMember2023-12-310001596783us-gaap:AdditionalPaidInCapitalMember2023-12-310001596783us-gaap:RetainedEarningsMember2023-12-310001596783us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-3100015967832023-12-310001596783us-gaap:CommonStockMember2022-07-012022-12-310001596783us-gaap:AdditionalPaidInCapitalMember2022-07-012022-12-3100015967832022-07-012022-12-310001596783us-gaap:AdditionalPaidInCapitalMember2021-07-012022-03-310001596783us-gaap:RetainedEarningsMember2022-07-012022-12-310001596783us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-07-012022-12-310001596783us-gaap:CommonStockMember2022-12-310001596783us-gaap:AdditionalPaidInCapitalMember2022-12-310001596783us-gaap:RetainedEarningsMember2022-12-310001596783us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-3100015967832022-12-31utr:Rate0001596783srt:ScenarioPreviouslyReportedMember2024-06-300001596783ctlt:RevisionAdjustmentsMember2024-06-3000015967832024-06-300001596783srt:RestatementAdjustmentMember2024-06-300001596783srt:ScenarioPreviouslyReportedMember2023-06-300001596783ctlt:RevisionAdjustmentsMember2023-06-300001596783us-gaap:ProductAndServiceOtherMember2023-07-012023-09-300001596783ctlt:BiologicsMemberctlt:ManufacturingCommercialProductSupplyMember2023-07-012023-09-300001596783ctlt:PharmaConsumerHealthMemberctlt:ManufacturingCommercialProductSupplyMember2023-07-012023-09-300001596783ctlt:TotalCatalentbeforeintersegmentrevenueeliminationMemberctlt:ManufacturingCommercialProductSupplyMember2023-07-012023-09-300001596783ctlt:DevelopmentServicesMemberctlt:BiologicsMember2023-07-012023-09-300001596783ctlt:DevelopmentServicesMemberctlt:PharmaConsumerHealthMember2023-07-012023-09-300001596783ctlt:DevelopmentServicesMemberctlt:TotalCatalentbeforeintersegmentrevenueeliminationMember2023-07-012023-09-300001596783us-gaap:OperatingSegmentsMemberctlt:BiologicsMember2023-07-012023-09-300001596783us-gaap:OperatingSegmentsMemberctlt:PharmaConsumerHealthMember2023-07-012023-09-300001596783ctlt:OperatingSegmentsExcludingIntersegmentEliminationMember2023-07-012023-09-300001596783us-gaap:IntersegmentEliminationMemberctlt:TotalCatalentSegmentMember2023-07-012023-09-300001596783us-gaap:OperatingSegmentsMember2023-07-012023-09-300001596783ctlt:BiologicsMemberctlt:ManufacturingCommercialProductSupplyMember2022-07-012022-09-300001596783ctlt:PharmaConsumerHealthMemberctlt:ManufacturingCommercialProductSupplyMember2022-07-012022-09-300001596783ctlt:TotalCatalentbeforeintersegmentrevenueeliminationMemberctlt:ManufacturingCommercialProductSupplyMember2022-07-012022-09-300001596783ctlt:DevelopmentServicesMemberctlt:BiologicsMember2022-07-012022-09-300001596783ctlt:DevelopmentServicesMemberctlt:PharmaConsumerHealthMember2022-07-012022-09-300001596783ctlt:DevelopmentServicesMemberctlt:TotalCatalentbeforeintersegmentrevenueeliminationMember2022-07-012022-09-300001596783us-gaap:OperatingSegmentsMemberctlt:BiologicsMember2022-07-012022-09-300001596783us-gaap:OperatingSegmentsMemberctlt:PharmaConsumerHealthMember2022-07-012022-09-300001596783ctlt:OperatingSegmentsExcludingIntersegmentEliminationMember2022-07-012022-09-300001596783us-gaap:IntersegmentEliminationMemberctlt:TotalCatalentSegmentMember2022-07-012022-09-300001596783ctlt:GeographicalMember2023-07-012023-09-300001596783srt:NorthAmericaMember2023-07-012023-09-300001596783srt:NorthAmericaMember2022-07-012022-09-300001596783srt:EuropeMember2023-07-012023-09-300001596783srt:EuropeMember2022-07-012022-09-300001596783ctlt:InternationalOtherMember2023-07-012023-09-300001596783ctlt:InternationalOtherMember2022-07-012022-09-300001596783ctlt:GreaterThanOneYearMemberMember2022-09-30xbrli:pure0001596783ctlt:MetricsMember2022-10-012022-10-010001596783ctlt:MetricsMember2022-10-010001596783ctlt:MetricsMemberus-gaap:CustomerRelationshipsMember2022-10-010001596783ctlt:MetricsMemberus-gaap:CustomerRelationshipsMember2022-10-012022-10-010001596783ctlt:BiologicsMember2023-06-300001596783ctlt:PharmaConsumerHealthMember2023-06-300001596783ctlt:BiologicsMember2023-07-012023-09-300001596783ctlt:PharmaConsumerHealthMember2023-07-012023-09-300001596783ctlt:BiologicsMember2023-09-300001596783ctlt:PharmaConsumerHealthMember2023-09-300001596783ctlt:TermLoanThreeFacilityDollarDenominatedMember2023-09-300001596783ctlt:TermLoanThreeFacilityDollarDenominatedMember2023-06-300001596783ctlt:RevolvingCreditFacilityTwoMember2023-09-300001596783ctlt:RevolvingCreditFacilityTwoMember2023-06-300001596783us-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:FairValueInputsLevel2Memberctlt:USDollarDenominated500SeniorNotesMember2023-09-300001596783us-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:FairValueInputsLevel2Memberctlt:USDollarDenominated500SeniorNotesMember2023-06-300001596783us-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:FairValueInputsLevel2Memberctlt:A2375SeniorEuroDenominatedNotesMember2023-09-300001596783us-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:FairValueInputsLevel2Memberctlt:A2375SeniorEuroDenominatedNotesMember2023-06-300001596783us-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:FairValueInputsLevel2Memberctlt:A3125SeniorUSDenominatedNotesMember2023-09-300001596783us-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:FairValueInputsLevel2Memberctlt:A3125SeniorUSDenominatedNotesMember2023-06-300001596783us-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:FairValueInputsLevel2Memberctlt:A3500SeniorUSDenominatedNotesMember2023-09-300001596783us-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:FairValueInputsLevel2Memberctlt:A3500SeniorUSDenominatedNotesMember2023-06-300001596783us-gaap:CapitalLeaseObligationsMember2023-09-300001596783us-gaap:CapitalLeaseObligationsMember2023-06-300001596783ctlt:OtherObligationsMember2023-09-300001596783ctlt:OtherObligationsMember2023-06-300001596783ctlt:DebtIssuanceCostsMemberus-gaap:CarryingReportedAmountFairValueDisclosureMember2023-09-300001596783ctlt:DebtIssuanceCostsMemberus-gaap:CarryingReportedAmountFairValueDisclosureMember2023-06-300001596783us-gaap:FairValueInputsLevel2Memberctlt:USDollarDenominated500SeniorNotesMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2023-09-300001596783us-gaap:FairValueInputsLevel2Memberctlt:USDollarDenominated500SeniorNotesMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2023-06-300001596783us-gaap:FairValueInputsLevel2Memberctlt:A2375SeniorEuroDenominatedNotesMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2023-09-300001596783us-gaap:FairValueInputsLevel2Memberctlt:A2375SeniorEuroDenominatedNotesMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2023-06-300001596783us-gaap:FairValueInputsLevel2Memberctlt:A3125SeniorUSDenominatedNotesMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2023-09-300001596783us-gaap:FairValueInputsLevel2Memberctlt:A3125SeniorUSDenominatedNotesMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2023-06-300001596783us-gaap:FairValueInputsLevel2Memberctlt:A3500SeniorUSDenominatedNotesMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2023-09-300001596783us-gaap:FairValueInputsLevel2Memberctlt:A3500SeniorUSDenominatedNotesMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2023-06-300001596783ctlt:SeniorSecuredCreditFacilitiesOtherMemberus-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:FairValueInputsLevel2Member2023-09-300001596783ctlt:SeniorSecuredCreditFacilitiesOtherMemberus-gaap:FairValueInputsLevel2Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2023-09-300001596783ctlt:SeniorSecuredCreditFacilitiesOtherMemberus-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:FairValueInputsLevel2Member2023-06-300001596783ctlt:SeniorSecuredCreditFacilitiesOtherMemberus-gaap:FairValueInputsLevel2Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2023-06-300001596783us-gaap:CarryingReportedAmountFairValueDisclosureMember2023-09-300001596783us-gaap:EstimateOfFairValueFairValueDisclosureMember2023-09-300001596783us-gaap:CarryingReportedAmountFairValueDisclosureMember2023-06-300001596783us-gaap:EstimateOfFairValueFairValueDisclosureMember2023-06-300001596783ctlt:DebtIssuanceCostsMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2023-09-300001596783ctlt:DebtIssuanceCostsMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2023-06-30ctlt:employees0001596783ctlt:BiologicsMember2022-07-012022-09-300001596783ctlt:PharmaConsumerHealthMember2022-07-012022-09-300001596783ctlt:CorporateAndEliminationsMember2023-07-012023-09-300001596783ctlt:CorporateAndEliminationsMember2022-07-012022-09-300001596783ctlt:EuroDenominatedDebtOutstandingMember2023-09-300001596783ctlt:USDenominatedTermLoanMember2023-09-300001596783ctlt:USDenominatedTermLoanMember2021-02-280001596783ctlt:USDenominatedTermLoanMember2023-06-300001596783us-gaap:FairValueInputsLevel1Member2023-09-300001596783us-gaap:FairValueInputsLevel2Member2023-09-300001596783us-gaap:FairValueInputsLevel3Member2023-09-300001596783us-gaap:FairValueInputsLevel1Member2023-06-300001596783us-gaap:FairValueInputsLevel2Member2023-06-300001596783us-gaap:FairValueInputsLevel3Member2023-06-300001596783us-gaap:AccumulatedTranslationAdjustmentMember2023-06-300001596783us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2023-06-300001596783us-gaap:AociDerivativeQualifyingAsHedgeExcludedComponentParentMember2023-06-300001596783us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2023-06-300001596783us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2023-07-012023-09-300001596783us-gaap:AociDerivativeQualifyingAsHedgeExcludedComponentParentMember2023-07-012023-09-300001596783us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2023-07-012023-09-300001596783ctlt:ACOIAccumulatedGainLossMarketableSecuritiesMember2023-07-012023-09-300001596783us-gaap:AccumulatedTranslationAdjustmentMember2023-09-300001596783us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2023-09-300001596783us-gaap:AociDerivativeQualifyingAsHedgeExcludedComponentParentMember2023-09-300001596783us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2023-09-300001596783us-gaap:AccumulatedTranslationAdjustmentMember2022-06-300001596783us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2022-06-300001596783us-gaap:AociDerivativeQualifyingAsHedgeExcludedComponentParentMember2022-06-300001596783ctlt:ACOIAccumulatedGainLossMarketableSecuritiesMember2022-06-300001596783us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2022-06-300001596783us-gaap:AccumulatedTranslationAdjustmentMember2022-07-012022-09-300001596783us-gaap:AociDerivativeQualifyingAsHedgeExcludedComponentParentMember2022-07-012022-09-300001596783us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2022-07-012022-09-300001596783us-gaap:AccumulatedTranslationAdjustmentMember2022-09-300001596783us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2022-09-300001596783us-gaap:AociDerivativeQualifyingAsHedgeExcludedComponentParentMember2022-09-300001596783ctlt:ACOIAccumulatedGainLossMarketableSecuritiesMember2022-09-300001596783us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2022-09-300001596783ctlt:TotalCatalentSubTotalOfSegmentReportingMember2023-07-012023-09-300001596783ctlt:TotalCatalentSubTotalOfSegmentReportingMember2022-07-012022-09-300001596783ctlt:CorporateAndEliminationsMember2023-09-300001596783ctlt:CorporateAndEliminationsMember2023-06-30
Table of Contents
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 ______________________________
FORM 10-Q
______________________________ 
ýQUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended September 30, 2023
or
¨TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
001-36587
(Commission File Number)
Image1.jpg
 _____________________________
Catalent, Inc.
(Exact name of registrant as specified in its charter)
_____________________________ 
     Delaware 20-8737688
        (State or other jurisdiction of incorporation or organization)(I.R.S. Employer Identification No.)
       14 Schoolhouse Road
                   Somerset, New Jersey08873
                     (Address of principal executive offices)_______
(Zip code)
(732) 537-6200
Registrant's telephone number, including area code
____________________________________ 

Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, $0.01 par value per share
CTLT
New York Stock Exchange
____________________________________
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes ¨  No
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).       Yes ¨  No
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer
Accelerated filer
¨
Non-accelerated filer
¨
Smaller reporting company
¨
Emerging growth company
¨
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).       ¨ Yes     No 



Table of Contents
On November 30, 2023, there were 180,641,272 shares of the Registrant's common stock, par value $0.01 per share, issued and outstanding.


Table of Contents
CATALENT, INC.
Index to Form 10-Q
For the Three Months Ended September 30, 2023
 
ItemPage
Part I.
Item 1.
Item 2.
Item 3.
Item 4.
Part II.
Item 1.
Item 1A.
Item 2.
Item 3.
Item 4.
Item 5.
Item 6.

3

Table of Contents
Special Note Regarding Forward-Looking Statements
In addition to historical information, this Quarterly Report on Form 10-Q of Catalent, Inc. (“Catalent” or the “Company”) contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), which are subject to the “safe harbor” created by those sections. All statements, other than statements of historical facts, included in this Quarterly Report on Form 10-Q are forward-looking statements. In some cases, you can identify these forward-looking statements by the use of words such as “outlook,” “believes,” “expects,” “potential,” “continues,” “may,” “will,” “should,” “could,” “seeks,” “approximately,” “predicts,” “intends,” “plans,” “estimates,” “anticipates” or the negative version of these words or other comparable words.
These statements are based on assumptions and assessments made by our management in light of their experience and their perception of historical trends, current conditions, expected future developments, and other factors they believe to be appropriate. Any forward-looking statement is subject to various risks and uncertainties. Accordingly, there are or will be important factors that could cause actual outcomes or results to differ materially from those indicated in these statements.

Some of the factors that may cause actual results, developments and business decisions to differ materially from those contemplated by such forward-looking statements include, but are not limited to, those summarized below, in addition to those described more fully (i) in Part II, “Item 1A. Risk Factors” and elsewhere in this report, (ii) from time to time in reports that we have filed or in the future may file with the Securities and Exchange Commission (the “SEC”), and (iii) under the section entitled “Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended June 30, 2023 (the "Fiscal 2023 10-K").

Risks Relating to Our Business and the Industry in Which We Operate

Actions of activist shareholders could impact the pursuit of our business strategies and adversely affect our results of operations, financial condition, or share price.

We anticipate being subject to increasing focus by our investors, regulators, customers, and other stakeholders on environmental, social, and governance (“ESG”) matters.

Any failure to implement fully, monitor, and continuously improve our quality management strategy could lead to quality or safety issues and expose us to significant costs, potential liability, and adverse publicity.

We have experienced, and may continue to experience, productivity issues and higher-than-expected costs at certain of our facilities, which have resulted in, and may continue to result in, material and adverse impacts on our financial condition and results of operations.

The declining demand for various COVID-19 vaccines and treatments from both patients and governments around the world has affected and may continue to affect sales of the COVID-19 products we manufacture and our financial condition.

The demand for our offerings depends in part on our customers’ research and development and the clinical and market success of their products.

Our results of operations are subject to fluctuations in the costs, availability, and suitability of the components of the products we manufacture, including active pharmaceutical ingredients, excipients, purchased components, and raw materials, and other supplies or equipment we need to run our business.

Our goodwill has been subject to impairment and may be subject to further impairment in the future, which could have a material adverse effect on our results of operations, financial condition, or future operating results.

Our ability to use our net operating loss carryforwards and certain other tax attributes may be limited.

We may acquire businesses and offerings that complement or expand our business or divest non-strategic businesses or assets. We may not be able to complete desired transactions, and such transactions, if executed, pose significant risks, including risks relating to our ability to successfully and efficiently integrate acquisitions or execute on dispositions and realize anticipated benefits therefrom. The failure to execute or realize the full benefits from any such transaction could have a negative effect on our operations and profitability.

We may become subject to litigation, other proceedings, and government investigations relating to us or our operations, and the ultimate outcome of any such matter may have an impact on our business, prospects, financial condition, and results of operations.
4

Table of Contents

Our global operations are subject to economic and political risks, including risks resulting from continuing inflation, disruptions to global supply chains, destabilization of a regional or national banking system, or from the Ukrainian-Russian war or the effect of the evolving nature of the recent war in Gaza between Israel and Hamas, which could affect the profitability of our operations or require costly changes to our procedures.

We use advanced information and communication systems to run our operations, compile and analyze financial and operational data, and communicate among our employees, customers, and counterparties, and the risks generally associated with information and communications systems could adversely affect our results of operations. We continuously work to install new, and upgrade existing, systems and provide employee awareness training around phishing, malware, and other cybersecurity risks to enhance the protections available to us, but such protections may be inadequate to address malicious attacks or inadvertent compromises affecting data security or the operability of such systems.

Artificial intelligence-based platforms present new risks and challenges to our business.
Our cash, cash equivalents, and financial investments could be adversely affected if the financial institutions in which we hold our cash, cash equivalents, and financial investments fail.

Risks Relating to Our Indebtedness

The size of our indebtedness and the obligations associated with it could adversely affect our ability to raise additional capital to fund our operations, limit our ability to react to changes in the economy or in our industry or to deploy capital to grow our business, expose us to interest-rate risk to the extent of our variable-rate debt, or prevent us from meeting our obligations under our indebtedness. These risks may be increased in a recessionary environment, particularly as sources of capital may become less available or more expensive.

Despite our high indebtedness level, we and our subsidiaries are still capable of incurring significant additional debt, which could further exacerbate the risks associated with our substantial indebtedness.

Our interest expense on our variable-rate debt may continue to increase if and to the extent that policymakers combat inflation through interest-rate increases on benchmark financial products.

Despite the limitations in our debt agreements, we retain the ability to take certain actions that may interfere with our ability to timely pay our substantial indebtedness.

We may not be able to pay our indebtedness when it becomes due.

We are currently using and may in the future use derivative financial instruments to reduce our exposure to market risks from changes in interest rates on our variable-rate indebtedness or changes in currency exchange rates, and any such instrument may expose us to risks related to counterparty credit worthiness or non-performance of these instruments.

Risks Relating to Ownership of Our Common Stock

We do not presently maintain effective disclosure controls and procedures due to material weaknesses we have identified in our internal controls over financial reporting. Failure to remediate these material weaknesses or any other material weakness or significant deficiencies have resulted in a revision of our financial statements, in the future could result in material misstatements in our financial statements and have caused, and in the future could cause us to fail to timely meet our periodic reporting obligations.

Our stock price has historically been and may continue to be volatile, and a holder of shares of our Common Stock may not be able to resell such shares at or above the price such stockholder paid, or at all, and could lose all or part of such investment as a result.

Future sales, or the perception of future sales, of our Common Stock, by us or our existing stockholders could cause the market price for our Common Stock to decline.

We are no longer eligible to use the Form S-3 registration statement, which could impair our capital-raising activities.

Provisions in our organizational documents could delay or prevent a change of control.

5

Table of Contents
We caution that the risks, uncertainties, and other factors referenced above may not contain all of the risks, uncertainties, and other factors that are important to you. In addition, we cannot assure you that we will realize the results, benefits, or developments that we expect or anticipate or, even if substantially realized, that they will result in the consequences or affect us or our business in the way expected. There can be no assurance that (i) we have correctly measured or identified all of the factors affecting our business or the extent of these factors’ likely impact, (ii) the available information with respect to these factors on which such analysis is based is complete or accurate, (iii) such analysis is correct, or (iv) our strategy, which is based in part on this analysis, will be successful. All forward-looking statements in this report apply only as of the date of this report or as of the date they were made and we undertake no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments, or otherwise, except as required by law.
Social Media
We use our website (catalent.com), Facebook page (facebook.com/CatalentPharmaSolutions), LinkedIn page (linkedin.com/company/catalent-pharma-solutions/) and Twitter account (@catalentpharma) as channels of distribution of information concerning our activities, our offerings, our various businesses, and other related matters. The information we post through these channels may be deemed material. Accordingly, investors should monitor these channels, in addition to following our press releases, SEC filings, and public conference calls and webcasts. The information contained on or accessible through our website, our social media channels, or any other website that we may maintain is not a part of this Quarterly Report.
6

Table of Contents
PART I.    FINANCIAL INFORMATION

ITEM 1.     FINANCIAL STATEMENTS

Catalent, Inc.
Consolidated Statements of Operations
(Unaudited; dollars in millions, except per share data)

Three Months Ended  
September 30,
20232022
Net revenue$982 $1,022 
Cost of sales813 764 
Gross margin169 258 
Selling, general, and administrative expenses205 196 
Goodwill impairment charges689  
Other operating expense, net1 2 
Operating (loss) earnings(726)60 
Interest expense, net58 32 
Other expense, net13 25 
(Loss) earnings before income taxes (797)3 
Income tax (benefit) expense(38)3 
Net loss$(759)$ 
Earnings (loss) per share:
Basic
Net loss$(4.19)$ 
Diluted
Net loss$(4.19)$ 












The accompanying notes are an integral part of these unaudited consolidated financial statements.
7

Table of Contents
Catalent, Inc.
Consolidated Statements of Comprehensive Loss
(Unaudited; dollars in millions)


Three Months Ended  
September 30,
20232022
Net loss$(759)$ 
Other comprehensive (loss) income, net of tax
Foreign currency translation adjustments(39)(135)
Net change in marketable securities 1 
Derivatives and hedges5 14 
Other comprehensive loss, net of tax(34)(120)
Comprehensive loss$(793)$(120)






















The accompanying notes are an integral part of these unaudited consolidated financial statements.
8

Table of Contents
Catalent, Inc.
Consolidated Balance Sheets
(Unaudited; in millions, except share and per share data)
 
September 30,
2023
June 30,
2023
ASSETS
Current assets:
Cash and cash equivalents $209 $280 
Trade receivables, net of allowance for credit losses of $48 and $46, respectively
830 1,002 
Inventories796 777 
Prepaid expenses and other 779 633 
Total current assets 2,614 2,692 
Property, plant, and equipment, net of accumulated depreciation of $1,647 and $1,596, respectively
3,723 3,682 
Other assets:
Goodwill2,316 3,039 
Other intangibles, net942 980 
Deferred income taxes100 55 
Other long-term assets328 329 
Total assets $10,023 $10,777 
LIABILITIES AND SHAREHOLDERS' EQUITY
Current liabilities:
Current portion of long-term obligations and other short-term borrowings $624 $536 
Accounts payable 367 424 
Other accrued liabilities 543 570 
Total current liabilities 1,534 1,530 
Long-term obligations, less current portion 4,322 4,313 
Pension liability99 100 
Deferred income taxes68 76 
Other liabilities159 147 
Commitment and contingencies (see Note 14)
Total liabilities6,182 6,166 
Shareholders' equity:
Common stock, $0.01 par value; 1.00 billion shares authorized at September 30, 2023 and June 30, 2023; 181 million and 180 million issued and outstanding at September 30, 2023 and June 30, 2023, respectively
2 2 
Preferred stock, $0.01 par value; 100 million shares authorized at September 30, 2023 and June 30, 2023;0 shares issued and outstanding at September 30, 2023 and June 30, 2023
  
Additional paid in capital4,724 4,701 
(Accumulated deficit) retained earnings(497)262 
Accumulated other comprehensive loss(388)(354)
Total shareholders' equity3,841 4,611 
Total liabilities and shareholders' equity$10,023 $10,777 


The accompanying notes are an integral part of these unaudited consolidated financial statements.
9

Table of Contents
Catalent, Inc.
Consolidated Statement of Changes in Shareholders' Equity
(Unaudited; dollars in millions, except share data in thousands)
 


Three Months Ended September 30, 2023
Shares of Common StockCommon StockAdditional Paid in CapitalAccumulated DeficitAccumulated Other Comprehensive LossTotal Shareholders' Equity
Balance at June 30, 2023180,273 $2 $4,701 $262 $(354)$4,611 
Share issuances related to stock-
     based compensation
248  — — —  
Stock-based compensation— — 19 — — 19 
Exercise of stock options— — 1 — — 1 
Employee stock purchase plan— — 3 — — 3 
Net loss— — — (759)— (759)
Other comprehensive income, net
of tax
— — — — (34)(34)
Balance at September 30, 2023180,521 $2 $4,724 $(497)$(388)$3,841 





Three Months Ended September 30, 2022
Shares of Common StockCommon StockAdditional Paid in CapitalRetained EarningsAccumulated Other Comprehensive LossTotal Shareholders' Equity
Balance at June 30, 2022179,302 $2 $4,649 $538 $(394)$4,795 
Share issuances related to stock-
     based compensation
599   — —  
Stock-based compensation— — 19 — — 19 
Net cash received, in lieu of equity, for
     tax withholding obligations
— — 2 — — 2 
Exercise of stock options— — 1 — — 1 
Employee stock purchase plan— — 3 — — 3 
Net earnings— — —  —  
Other comprehensive loss, net
       of tax
— — — — (120)(120)
Balance at September 30, 2022179,901 $2 $4,674 $538 $(514)$4,700 





The accompanying notes are an integral part of these unaudited consolidated financial statements.
10

Table of Contents
Catalent, Inc.
Consolidated Statements of Cash Flows
(Unaudited; dollars in millions)
Three Months Ended September 30,
20232022
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss$(759)$ 
Adjustments to reconcile net loss to net cash from operations:
Depreciation and amortization112 99 
Goodwill impairment charges689  
Non-cash foreign currency transaction loss, net9 27 
Amortization of debt issuance costs
2 2 
Impairments charges and loss/gain on sale of assets, net
(1)(2)
Stock-based compensation
19 19 
Benefit from deferred income taxes(44)(4)
Provision for bad debts and inventory10 28 
Change in operating assets and liabilities:
Decrease in trade receivables160 31 
Increase in inventories(31)(85)
Decrease in accounts payable(73)(52)
Other assets/accrued liabilities, net—current and non-current
(163)(155)
Net cash used in operating activities(70)(92)
CASH FLOWS USED IN INVESTING ACTIVITIES:
Acquisition of property, equipment, and other productive assets(84)(149)
Proceeds from maturity of marketable securities 24 
Proceeds from sale of property and equipment1 6 
(Payment) proceeds for investments(1)3 
Net cash used in investing activities(84)(116)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from borrowing115 75 
Payments related to long-term obligations(35)(7)
Financing fees paid
(1) 
Cash received, in lieu of equity, for tax-withholding obligations 2 
Exercise of stock options1 1 
Other financing activities18 3 
Net cash provided by financing activities98 74 
Effect of foreign currency exchange on cash and cash equivalents(15)(34)
NET DECREASE IN CASH AND CASH EQUIVALENTS(71)(168)
CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD280 449 
CASH AND CASH EQUIVALENTS AT END OF PERIOD$209 $281 
SUPPLEMENTARY CASH FLOW INFORMATION:
Interest paid$65 $46 
Income taxes paid, net$19 $11 
Non-cash purchase of property, equipment, and other productive assets$21 $22 
    







The accompanying notes are an integral part of these unaudited consolidated financial statements.
11

Table of Contents
Catalent, Inc.
Notes to Unaudited Consolidated Financial Statements
1.    BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Business
Catalent, Inc. (Catalent or the Company) directly and wholly owns PTS Intermediate Holdings LLC (Intermediate Holdings). Intermediate Holdings directly and wholly owns Catalent Pharma Solutions, Inc. (Operating Company). The financial results of Catalent are comprised of the financial results of Operating Company and its subsidiaries on a consolidated basis.
Basis of Presentation
The accompanying unaudited consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States (“U.S. GAAP) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and notes required by U.S. GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included. Operating results for the three months ended September 30, 2023 are not necessarily indicative of the results that may be expected for the year ending June 30, 2024. The consolidated balance sheet at June 30, 2023 has been derived from the audited consolidated financial statements at that date but does not include all of the information and footnotes required by U.S. GAAP for complete financial statements. For further information on the Company's accounting policies and footnotes, refer to the consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended June 30, 2023 filed with the Securities and Exchange Commission (the “SEC”) on December 8, 2023.
Reportable Segments
Set forth below is a summary description of the Company's two current operating and reportable segments.

Biologics—The Biologics segment provides development and manufacturing for biologic proteins; cell, gene, and other nucleic acid therapies; plasmid DNA ("pDNA"); induced pluripotent stem cells ("iPSCs"), and oncolytic viruses; and vaccines. It also provides formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; analytical development and testing services for large molecules.

Pharma and Consumer Health—The Pharma and Consumer Health segment comprises the Company’s market-leading capabilities for complex oral solids, softgel formulations, Zydis® fast-dissolve technologies, and gummy, soft chew, and lozenge dosage forms; formulation, development, and manufacturing platforms for oral, nasal, inhaled, and topical dose forms; and clinical trial development and supply services.

Each segment reports through a separate management team and ultimately reports to the Company's President and Chief Executive Officer, who is designated as the Chief Operating Decision Maker for segment reporting purposes. The Company's operating segments are the same as its reportable segments.

Foreign Currency Translation
The financial statements of the Company’s operations are generally measured using the local currency as the functional currency. Adjustments to translate the assets and liabilities of operations outside the United States (“U.S.”) into U.S. dollars are accumulated as a component of other comprehensive income utilizing period-end exchange rates. Since July 1, 2018, the Company has accounted for its Argentine operations as highly inflationary.
12

Table of Contents
Concentrations of Credit Risk and Major Customers
Concentration of credit risk, with respect to accounts receivable, is limited due to the large number of customers and their dispersion across different geographic areas. The customers are primarily concentrated in the pharmaceutical, biopharmaceutical and consumer products industries. The Company does not normally require collateral or any other security to support credit sales. The Company performs ongoing credit evaluations of its customers’ financial conditions and maintains reserves for credit losses. Such losses historically have been within the Company’s expectations.
As of September 30, 2023 and June 30, 2023, the Company had one customer that represented 30% and 20%, respectively, of its aggregate net trade receivables and current contract asset values, primarily associated with the Company's Biologics segment. After performing a risk assessment of this customer, the Company has determined that a reserve is not warranted as of September 30, 2023. Additionally, the Company had one customer in its Biologics segment that represented approximately 16% of consolidated net revenue during the three months ended September 30, 2023. That customer did not exceed 10% of net revenue during the three months ended September 30, 2022.
Depreciation
Depreciation expense was $78 million and $66 million for the three months ended September 30, 2023 and 2022, respectively. Depreciation expense includes amortization of assets related to finance leases. The Company charges repairs and maintenance costs to expense as incurred.
Amortization
Amortization expense related to other intangible assets was $34 million and $33 million for the three months ended September 30, 2023 and 2022, respectively.
Research and Development Costs
The Company expenses research and development costs as incurred. Research and development costs amounted to $4 million and $5 million for the three months ended September 30, 2023 and 2022, respectively.
2.    REVENUE RECOGNITION

The Company recognizes revenue in accordance with ASC 606, Revenue from Contracts with Customers. The Company generally earns its revenue by supplying goods or providing services under contracts with its customers in three primary revenue streams: manufacturing and commercial product supply, development services, and clinical supply services. The Company measures the revenue from customers based on the consideration specified in its contracts, excluding any sales incentive or amount collected on behalf of a third party, that the Company expects to be entitled to receive in exchange for transferring the promised goods to and/or performing services for the customer (the “Transaction Price”). To the extent the Transaction Price includes variable consideration, the Company estimates the amount of variable consideration that should be included in the Transaction Price utilizing either the expected value method or the most likely amount method, depending on which method is expected to better predict the amount of consideration to which the Company will be entitled. The value of variable consideration is included in the Transaction Price if, and to the extent, it is probable that a significant reversal of the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. These estimates are re-assessed each reporting period, as required, and any adjustment required is recorded on a cumulative catch-up basis, which would affect revenue and net income in the period of adjustment.

The Company’s customer contracts generally include provisions entitling the Company to a termination penalty when the customer terminates prior to the contract’s nominal end date. The termination penalties in customer contracts vary but are generally considered substantive for accounting purposes and create enforceable rights and obligations throughout the stated durations of the contracts. The Company accounts for a contract termination as a contract modification in the period in which the customer gives notice of termination. The determination of the contract termination penalty is based on the terms stated in the relevant customer agreement. As of the modification date, the Company updates its estimate of the Transaction Price using the expected value method, subject to constraints, and to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. These estimates are re-assessed each reporting period, as required, and any adjustment required is recorded on a cumulative catch-up basis, which would affect revenue and net income in the period of adjustment.

Where multiple performance obligations exist in a single contract, the Company allocates consideration to each performance obligation using the “relative standalone selling price” as defined under ASC 606. Generally, the Company utilizes observable standalone selling prices in its allocations of consideration. If observable standalone selling prices are not available, the Company estimates the applicable standalone selling price using a cost-plus-margin approach or an adjusted market
13

Table of Contents
assessment approach, in each case, representing the amount that the Company believes the market is willing to pay for the applicable service. Payment is typically due 30 to 45 days following the invoice date, based on the payment terms set forth in the applicable customer agreement.

The Company generally expenses sales commissions as incurred because either the amortization period is one year or less, or the balance with an amortization period greater than one year is not material.

Customer contracts that include commitments by the Company to make facility space or equipment available may be deemed to include lease components, which are evaluated under ASC 842, Leases. For arrangements that contain both lease and non-lease components, consideration in the contract is allocated on a relative standalone selling-price basis. Determining the lease term and contract term of non-lease components, as well as the variable and fixed consideration in these arrangements, including when variability is resolved, often requires management judgment in order to determine the allocation to the lease and non-lease components.
Manufacturing & Commercial Product Supply Revenue

Manufacturing and commercial product supply revenue consists of revenue earned by manufacturing products supplied to customers under long-term commercial supply arrangements. In these arrangements, the customer typically owns and supplies the active pharmaceutical ingredient (“API”) or other proprietary materials used in the manufacturing process. The contract generally includes the terms of the manufacturing services and related product quality assurance procedures to comply with regulatory requirements. Due to the regulated nature of the Company’s business, these contract terms are highly interdependent and, therefore, are considered to be a single combined performance obligation. The transaction price is generally stated in the agreement as a fixed price per unit, with no contractual provision for a refund or price concession. In most circumstances, control is transferred to the customer over time, creating a corresponding right to recognize the related revenue, because there is no alternative use to the Company for the asset created and the Company has an enforceable right to payment for performance completed as of that date. The selection of the method for measuring progress towards the completion of the Company’s performance obligation requires judgment and is based on the nature of the products to be manufactured. For the majority of the Company’s arrangements, progress is measured based on the units of product that have successfully completed the contractually required product quality assurance process, because the conclusion of that process defines the time when the applicable contract and the related regulatory requirements permit the customer to exercise control over the product’s disposition. The customer is typically responsible for arranging the shipping and handling of product following completion of the quality assurance process. Payment is typically due 30 to 45 days after invoice date, based on the payment terms set forth in the applicable customer agreement.

Beginning in the third quarter of fiscal 2023, the Company began recognizing commercial revenue for certain contracts in its Biologics segment that have a notably long manufacturing cycle, and for which the customer exercises control over the product throughout the manufacturing process. For these contracts, revenue is recognized over time and progress is measured using an input method based on effort expended, which provides an appropriate depiction of the Company’s progress toward fulfilling its performance obligation.

Development Services and Clinical Supply Revenue

Development services contracts generally take the form of short-term, fee-for-service arrangements. Performance obligations vary, but frequently include biologic cell-line development, performing formulation, analytical stability, or other services related to product development, and providing manufacturing services for products that are under development or otherwise not intended for commercial sale. They can also include a combination of the following services: the manufacturing, packaging, storage, distribution, destruction, and inventory management of customer clinical trial material, as well as the sourcing of comparator drug products on behalf of customers to be used in clinical trials to compare performance with the drug under clinical investigation. The transaction prices for these arrangements are fixed and include amounts stated in the contracts for each promised service, and each service is generally considered to be a separate performance obligation. In most instances, the Company recognizes revenue over time because there is no alternative use to the Company for the asset created and the Company has an enforceable right to payment for performance completed as of that date.

The Company measures progress toward the completion of its performance obligations satisfied over time based on the nature of the services to be performed. For certain types of arrangements, revenue is recognized over time and measured using an output method based on the completion of tasks and activities that are performed to satisfy a performance obligation. For certain types of arrangements, revenue is recognized over time and measured using an input method based on effort expended. Each of these methods provides an appropriate depiction of the Company’s progress toward fulfilling its performance obligations for its respective arrangement. In certain development services arrangements that require a portion of the contract consideration to be received in advance at the commencement of the contract, such advance payment is initially recorded as a
14

Table of Contents
contract liability. In certain clinical supply arrangements, revenue is recognized at the point in time when control transfers, which occurs upon either the delivery of the related output of the service to the customer or the completion of quality testing with respect to the product, and the Company has an enforceable right to payment based on the terms of the arrangement.

The Company records revenue for comparator sourcing arrangements on a net basis because it is acting as an agent that does not control the product or service before it is transferred to the customer. Payment for comparator sourcing activity is typically received in advance at the commencement of the contract and is initially recorded as a contract liability.

The Company generally expenses sales commissions as incurred because either the amortization period is one year or less, or the balance with an amortization period greater than one year is not material.
The following tables reflect net revenue for the three months ended September 30, 2023 and 2022, by type of activity and reportable segment (in millions):
Three Months Ended September 30, 2023BiologicsPharma and Consumer HealthTotal
Manufacturing & commercial product supply$282 $334 $616 
Development services & clinical supply166 200 366 
Total$448 $534 $982 
Inter-segment revenue elimination 
Combined net revenue$982 
Three Months Ended September 30, 2022BiologicsPharma and Consumer HealthTotal
Manufacturing & commercial product supply$95 $314 $409 
Development services & clinical supply428 185 613 
Total$523 $499 $1,022 
Inter-segment revenue elimination 
Combined net revenue$1,022 



The following table allocates revenue by the location where the goods were made or the service performed:

Three Months Ended  
September 30,
(Dollars in millions)20232022
United States$645 $697 
Europe274 274 
Other88 82 
Elimination of revenue attributable to multiple locations(25)(31)
Total$982 $1,022 
15

Table of Contents
Contract Liabilities
Contract liabilities relate to cash consideration that the Company receives in advance of satisfying the related performance obligations. The contract liabilities balances (current and non-current) as of September 30, 2023 and June 30, 2023 are as follows:
(Dollars in millions)
Balance at June 30, 2023$180 
Balance at September 30, 2023$189 
Revenue recognized in the period from amounts included in contracts liability at the beginning of the period:$(75)

Contract liabilities that will be recognized within 12 months of September 30, 2023 are accounted for in Other accrued liabilities and those that will be recognized longer than 12 months after September 30, 2023 are accounted for in Other liabilities.

Contract Assets
Contract assets primarily relate to the Company's conditional right to receive consideration for services that have been performed for customers as of September 30, 2023 relating to the Company's development services but had not yet been invoiced as of September 30, 2023. Contract assets are transferred to trade receivables, net when the Company’s right to receive the consideration becomes unconditional. Contract assets totaled $536 million and $417 million as of September 30, 2023 and June 30, 2023, respectively. Contract assets expected to transfer to trade receivables within 12 months are accounted for within Prepaid expenses and other. Contract assets expected to transfer to trade receivables longer than 12 months are accounted for within Other long-term assets.
As of September 30, 2023, the Company's aggregate contract asset balance increased $119 million or 29% compared to June 30, 2023. The majority of this increase is related to large development and commercial programs in the Biologics segment, such as manufacturing and development services for gene therapy offerings, where revenue is recorded over time and the ability to invoice customers is dictated by contractual terms. As of September 30, 2023, the Company recorded no reserve against its aggregate contract asset balance.
Performance Obligations

Remaining performance obligations represent firm orders for future development services as well as manufacturing and commercial product supply, including minimum volume commitments, for which there are incomplete performance obligations for work not yet completed under executed contracts. Remaining performance obligations as of September 30, 2023 were $545 million. The Company expects to recognize approximately 44% of the remaining performance obligations in existence as of September 30, 2023 after June 30, 2024.
3.    BUSINESS COMBINATIONS
Metrics Contract Services Acquisition

In October 2022, the Company acquired 100% of Metrics Contract Services (“Metrics”) from Mayne Pharma Group Limited for $474 million in cash. Metrics, based in Greenville, North Carolina, is an oral solids development and manufacturing business specializing in the manufacture of drugs containing highly potent active pharmaceutical ingredients. The operations and facility acquired have become part of the Company’s Pharma and Consumer Health segment.

The Company accounted for the Metrics transaction using the acquisition method in accordance with ASC 805, Business Combinations. The Company funded this acquisition with a portion of the proceeds of an October 2022 drawdown from its senior secured revolving credit facility. The Company estimated fair values at the date of acquisition for the allocation of consideration to the net tangible and intangible assets acquired and liabilities assumed.

The purchase price allocation to assets acquired and liabilities assumed in the transaction is as follows:

16

Table of Contents
(Dollars in millions)Final Purchase Price Allocation
Trade receivables, net$15 
Inventories5 
Property, plant, and equipment195 
Other intangibles, net52 
Other, net(12)
Goodwill219 
Total assets acquired and liabilities assumed$474 
The carrying value of trade receivables, inventory, and trade payables, as well as certain other current and non-current assets and liabilities generally represented the fair value at the date of acquisition.
Other intangibles, net consists of customer relationships of $52 million, which were valued using the multi-period, excess-earnings method, a method that values the intangible asset using the present value of the after-tax cash flows attributable to the intangible asset only. The significant assumptions used in developing the valuation included the estimated annual net cash flows (including application of an appropriate margin to forecasted revenue, selling and marketing costs, return on working capital, contributory asset charges, and other factors), the discount rate that appropriately reflects the risk inherent in each future cash flow stream, and an assessment of the asset’s life cycle, as well as other factors. The assumptions used in the financial forecasts were based on historical data, supplemented by current and anticipated growth rates, management plans, and market-comparable information. Fair-value determinations require considerable judgment and are sensitive to changes in underlying assumptions and factors. The customer relationship intangible asset has a weighted average useful life of 12 years.

Property, plant, and equipment was valued using the cost approach, which is based on current replacement and/or reproduction cost of the asset as new, less depreciation attributable to physical, functional, and economic factors. The Company then determined the remaining useful life based on the anticipated life of the asset and Company policy for similar assets.

Goodwill was allocated to the Pharma and Consumer Health segment. Goodwill is mainly comprised of the growth from an expected increase in capacity utilization and potential new customers. The goodwill resulting from the Metrics acquisition is not deductible for tax purposes.

Results of the business acquired were not material to the Company's consolidated statement of operations, financial position, or cash flows for the three months ended September 30, 2023.

4.    GOODWILL
The following table summarizes the changes between June 30, 2023 and September 30, 2023 in the carrying amount of goodwill in total and by segment:
(Dollars in millions)BiologicsPharma and Consumer HealthTotal
Balance at June 30, 2023$1,563 $1,476 $3,039 
Foreign currency translation adjustments(13)(21)(34)
Impairment (1)
(392)(297)(689)
Balance at September 30, 2023$1,158 $1,158 $2,316 
(1) Represents gross impairment charges in the period. Accumulated goodwill impairment charges amount to $899 million.
Goodwill Impairment Charges
17

Table of Contents
As a result of the Consumer Health reporting unit's underperformance of recent operating results relative to expectations, the current macroeconomic conditions impacting the consumer health and biotechnology industries, and increased interest rates, the Company assessed the current and future economic outlook as of September 30, 2023 for its reporting units in its Pharma and Consumer Health and Biologics segments and identified indicators for impairment of the goodwill previously recorded for two of its reporting units. The evaluation began with a qualitative assessment of the Company's Consumer Health and Biomodalities reporting units to determine if it was more likely than not that the fair value of the reporting units was less than its carrying value. The qualitative assessment did not indicate that it was more likely than not that the fair value exceeded the carrying value in its Consumer Health and Biomodalities reporting units, which led to a quantitative assessment for the corresponding reporting units.

The Company estimated the fair value of its reporting units using a combination of the income and market approaches. In performing the goodwill impairment test, the Company used a terminal revenue growth rate of 3.5% and discount rates ranging from 9% to 10% in its estimation of fair value. The evaluation performed resulted in impairment charges of $689 million with respect to the Consumer Health and Biomodalities reporting units.
While the Company believes the assumptions it used were reasonable and commensurate with the views of a market participant, changes in key assumptions, including increasing the discount rate, lowering forecasts for revenue and operating margin or lowering the long-term growth rate could lead to the conclusion that an additional impairment was appropriate.
In conjunction with the goodwill impairment test performed as of September 30, 2023, the Company identified indicators of impairment related to its definite-lived intangibles in its Biomodalities, Bioproduct Delivery, Pharma and Product Delivery, Clinical Development and Supply, and Consumer Health reporting units. However, the results of the analysis did not result in an impairment charge.
18

Table of Contents
5.    LONG-TERM OBLIGATIONS AND SHORT-TERM BORROWINGS
Long-term obligations and short-term borrowings consisted of the following at September 30, 2023 and June 30, 2023:
(Dollars in millions)MaturitySeptember 30, 2023June 30, 2023
Senior secured credit facilities
Term loan facility B-3 (7.437% as of September 30, 2023)February 2028$1,415 $1,418 
Revolving credit facility (1) (7.673% as of September 30, 2023)
November 2027585 500 
5.000% senior notes due 2027July 2027500 500 
2.375% Euro senior notes due 2028(2)
March 2028872 904 
3.125% senior notes due 2029February 2029550 550 
3.500% senior notes due 2030April 2030650 650 
Financing lease obligations2023 to 2038375 341 
Other obligations(3)
2023 to 202837 25 
Unamortized discount and debt issuance costs(38)(39)
Total debt$4,946 $4,849 
Less: current portion of long-term obligations and other short-term
     borrowings (1)
624 536 
Long-term obligations, less current portion $4,322 $4,313 
(1)    During the three months ended September 30, 2023, the Company drew down $115 million on its revolving credit facility to supplement operating cash flows, of which $30 million was repaid during the three months ended September 30, 2023. The Company has elected to classify the borrowing on its revolving credit facility as current as it intends to repay a portion of the borrowing using cash flows from operations and/or refinance the borrowing within the next twelve months.
(2)    The change in the carrying value of this euro-denominated debt was due to fluctuations in foreign currency exchange rates.
(3)    The increase in other obligations is associated with $15 million in proceeds from a failed sale-leaseback transaction that occurred in the three months ended September 30, 2023.
The Revolving Credit Facility requires compliance with a net leverage covenant when there is a 30% or more draw outstanding at a period end. As of September 30, 2023, we were in compliance with all material covenants under the Credit Agreement.
On September 27, 2023, Operating Company entered into Amendment No. 9 to its Amended and Restated Credit Agreement (“Amendment No. 9”) by and among Operating Company, PTS Intermediate, the subsidiaries of Operating Company party thereto, JPMorgan Chase Bank, N.A., as the administrative agent, collateral agent, swing line lender, and letter of credit issuer, and the lenders and other parties thereto, which Amendment No. 9 amends the Credit Agreement to extend the deadlines by which the Operating Company is required to deliver to the administrative agent (i) its audited financial statements as at the end of and for the fiscal year ended June 30, 2023, together with the auditor’s report and opinion on such audited financial statements, to November 27, 2023, and (ii) its unaudited financial statements as at the end of and for the fiscal quarter ending September 30, 2023 to January 13, 2024.
19

Table of Contents

In addition to outstanding borrowings under the Revolving Credit facility, the available capacity under the Revolving Credit Facility is further reduced by the aggregate value of all outstanding letters of credit under the Credit Agreement. As of September 30, 2023, Operating Company had $509 million of unutilized capacity under the Revolving Credit Facility, due to $585 million in short-term borrowings outstanding and $6 million of outstanding letters of credit.
Measurement of the Estimated Fair Value of Debt

The estimated fair value of the Company’s senior secured credit facilities and other senior indebtedness is classified as a Level 2 determination (see Note 10, Fair Value Measurements, for a description of the method by which fair value classifications are determined) in the fair-value hierarchy and is calculated by using a discounted cash flow model with a market interest rate as a significant input. The carrying amounts and the estimated fair values of the Company’s principal categories of debt as of September 30 2023 and June 30, 2023 are as follows:

September 30, 2023June 30, 2023
(Dollars in millions)Fair Value Measurement
Carrying
Value
Estimated Fair
Value
Carrying
Value
Estimated Fair
Value
5.000% senior notes due 2027Level 2$500 $476 $500 $482 
2.375% Euro senior notes due 2028Level 2872 775 904 784 
3.125% senior notes due 2029Level 2550 482 550 481 
3.500% senior notes due 2030Level 2650 579 650 566 
Senior secured credit facilities & otherLevel 22,412 2,233 2,284 2,141 
Subtotal$4,984 $4,545 $4,888 $4,454 
Unamortized discount and debt issuance
   costs
(38) (39) 
Total debt$4,946 $4,545 $4,849 $4,454 

6.    LOSS PER SHARE
The Company computes earnings(loss) per share of the Company’s common stock, par value $0.01 (the “Common Stock”) using the treasury stock method. Diluted net (loss) earnings per share is computed using the weighted average number of shares of Common Stock outstanding plus the weighted average number of shares of Common Stock that would be issued assuming exercise or conversion of all potentially dilutive instruments. Dilutive securities having an anti-dilutive effect on diluted net earnings per share are excluded from the calculation. The dilutive effect of the securities that are issuable under the Company’s equity incentive plans are reflected in diluted earnings per share by application of the treasury stock method. The reconciliations between basic and diluted earnings per share attributable to Catalent common shareholders for the three months ended September 30, 2023 and 2022, respectively, are as follows:

Three Months Ended  
September 30,
(In millions except per share data)20232022
Net loss$(759)$ 
Weighted average shares outstanding - basic181 180 
Weighted average dilutive securities issuable - stock plans 1 
Weighted average shares outstanding - diluted181 181 
Loss per share: 
Basic$(4.19)$ 
Diluted$(4.19)$ 

Shares with an antidilutive effect on the weighted average shares outstanding for the three months ended September 30, 2023 and 2022 were not material.
20

Table of Contents
7.    OTHER EXPENSE, NET
The components of other expense, net for the three months ended September 30, 2023 and 2022 are as follows:
Three Months Ended  
September 30,
(Dollars in millions)20232022
Foreign currency losses (1)
$12 $24 
     Other 1 1 
Total other expense, net$13 $25 

(1)    Foreign currency remeasurement gains/losses include both cash and non-cash transactions.
8.     RESTRUCTURING COSTS
From time to time, the Company implements plans to restructure certain operations, both domestically and internationally. The restructuring plans focused on various aspects of operations, including, among others, closing and consolidating certain manufacturing operations, rationalizing headcount and aligning operations in a strategic and more cost-efficient structure. In addition, the Company may incur restructuring charges in the future in cases where a material change in the scope of operation with its business occurs. Employee-related restructuring costs consist primarily of severance costs and also include outplacement services provided to employees who have been involuntarily terminated and duplicate payroll costs during transition periods. Facility exit and other such restructuring costs consist of equipment relocation costs and costs associated with planned facility expansions and closures to streamline Company operations.
During the fiscal year ended June 30, 2023, the Company adopted plans to reduce costs, consolidate facilities, and optimize its infrastructure across the organization. During the three months ended September 30, 2023, the Company extended its restructuring efforts to reduce costs and headcount in both its Biologics and Pharma and Consumer Health segments. In connection with these restructuring plans, the Company reduced its headcount by approximately 50 employees and incurred cumulative employee-related charges of approximately $2 million, primarily associated with cash severance programs through September 30, 2023.
Restructuring costs for the three months ended September 30, 2023 and 2022 were recorded in Other Operating Expense in the Consolidated Statement of Operations.
The following table summarizes the charges recorded within restructuring costs:
Three Months Ended  
September 30,
(Dollars in millions) 
20232022
Restructuring costs:  
       Employee-related reorganization$2 $2 
       Facility exit and other costs 2 
Total restructuring costs$2 $4 
The following table summarizes the charges recorded within restructuring costs by segment. These amounts are excluded from Segment EBITDA as described in Note 15, Segment Information.
21

Table of Contents
Three Months Ended  
September 30,
(Dollars in millions) 
20232022
Restructuring costs:
Biologics$1 $ 
Pharma and Consumer Health1 3 
Non-segment (Corporate) 1 
Total restructuring costs$2 $4 

The following tables illustrates the change in the employee separation-related liability associated with the plans.

Employee-related restructuring
(Dollars in millions) 
Balance, June 30, 2023$19 
Charges to income2 
Payments(9)
Balance, September 30, 2023$12 
9.    DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES
Risk Management Objective of Using Derivatives
The Company is exposed to fluctuations in the currency exchange rates applicable to its investments in operations outside the U.S. While the Company does not actively hedge against changes in foreign currency, the Company has mitigated exposure from its investments in its European operations by denominating a portion of its debt in euros. At September 30, 2023, the Company had euro-denominated debt outstanding of $872 million (U.S. dollar equivalent), which is designated and qualifies as a hedge against its net investment in its European operations. For non-derivatives designated and qualifying as net investment hedges, the effective portion of translation gains or losses are reported in accumulated other comprehensive loss as part of the cumulative translation adjustment. The following table summarizes net investment hedge activity during the three months ended September 30, 2023 and 2022.
Three Months Ended  
September 30,
(Dollars in millions)20232022
Unrealized foreign exchange gain (loss) within other comprehensive income
$32 $81 
The net accumulated gain on the instrument designated as a hedge as of September 30, 2023 within other comprehensive loss was approximately $129 million. Amounts are reclassified out of accumulated other comprehensive loss into earnings when the entity to which the gains and losses relate is either sold or substantially liquidated.
Interest-Rate Swap
In February 2021, the Company entered into an interest-rate swap agreement with Bank of America N.A. (the “2021 Rate Swap”) as a hedge against the economic effect of a portion of the variable interest obligation associated with its Term B-3 Loans. The 2021 Rate Swap effectively fixed the rate of interest payable on that portion of the Term B-3 Loans, thereby reducing the impact of future interest rate changes on future interest expense. As a result of the 2021 Rate Swap, the variable portion of the applicable interest rate on $500 million of the Term B-3 Loans is now effectively fixed at 0.9985%.
To conform with the adoption of Topic 848, Reference Rate Reform and the Eighth Amendment, the Company amended the 2021 Rate Swap in June 2023 (the “2023 Rate Swap”). The 2023 Rate Swap continues to effectively fix the rate of interest payable on the same portion of our U.S. dollar-denominated term loans under our senior secured credit facilities. As a result of the 2023 Rate Swap, the variable portion of the applicable interest rate on $500 million of the U.S. dollar-denominated term loans is now effectively fixed at 0.9431%.
22

Table of Contents
The 2023 Rate Swap continues to qualify for a cash-flow hedge. The Company evaluates hedge effectiveness at the inception of the hedge and on an ongoing basis. The cash flows associated with the 2023 Rate Swap amendment is reported in cash provided by operating activities in the consolidated statements of cash flows. The unrealized gain recorded in stockholder's equity from marking the 2021 Rate Swap to market during the three months ended September 30, 2023 was $5 million.
A summary of the estimated fair value of the 2021 Rate Swap reported in the consolidated balance sheets is stated in the table below:
September 30, 2023June 30, 2023
(Dollars in millions)Balance Sheet ClassificationEstimated Fair ValueBalance Sheet ClassificationEstimated Fair Value
Interest-rate swapOther long-term assets$67 Other long-term assets$62 

10. FAIR VALUE MEASUREMENTS
ASC 820, Fair Value Measurement, defines fair value as the exit price that would be received to sell an asset or paid to transfer a liability. Fair value is a market-based measurement that should be determined using assumptions that market participants would use in pricing an asset or liability. Valuation techniques used to measure fair value should maximize the use of observable inputs and minimize the use of unobservable inputs. To measure fair value, the Company uses the following fair value hierarchy based on three levels of inputs, of which Level 1 and Level 2 are considered observable and Level 3 is considered unobservable:
Level 1 – Quoted prices in active markets for identical assets or liabilities.                      
Level 2 – Inputs other than Level 1 that are observable for the asset or liability, either directly or indirectly, such as quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data by correlation or other means.                      
Level 3 – Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. Value is determined using pricing models, discounted cash flow methodologies, or similar techniques and also includes instruments for which the determination of fair value requires significant judgment or estimation.
Assets and Liabilities Measured at Fair Value on a Recurring Basis
The carrying amounts of cash and cash equivalents, accounts receivable, accounts payable and accrued expenses of the Company approximate fair value based on the short maturities of these instruments.
The Company evaluates its financial assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level of classification as of the end of each reporting period. The following table sets forth the Company’s financial assets and liabilities that were measured at fair value on a recurring basis and the fair value measurement for such assets and liabilities at September 30, 2023 and June 30, 2023:

(Dollars in millions)Basis of Fair Value Measurement
September 30, 2023TotalLevel 1Level 2Level 3
Assets:
Interest-rate swap$67 $ $67 $ 
Trading securities2 2   
June 30, 2023
Assets:
Interest-rate swap$62 $ $62 $ 
Trading securities1 1   
23

Table of Contents
The fair value of the 2021 Rate Swap was determined, and the fair value of the 2023 Rate Swap will be determined, at the end of each reporting period based on valuation models that use interest rate yield curves and discount rates as inputs. The discount rates are based on U.S. deposit or U.S. Treasury rates. The significant inputs used in the valuation models are readily available in public markets or can be derived from observable market transactions, and the valuation is therefore classified as Level 2 in the fair-value hierarchy.
Assets and Liabilities Measured at Fair Value on a Non-Recurring Basis

Long-lived assets, goodwill, and other intangible assets are subject to non-recurring fair value measurement for the evaluation of potential impairment. There was no non-recurring fair value measurement during the three months ended September 30, 2023 and September 30, 2022.
11.    INCOME TAXES
The Company accounts for income taxes in accordance with ASC 740, Income Taxes. Generally, fluctuations in the effective tax rate are due to changes in relative amounts of U.S. and non-U.S. pretax income, the tax impact of special items, and other discrete tax items. Discrete items include, but are not limited to, changes in non-U.S. statutory tax rates, amortization of certain assets, changes in the Company’s reserve for uncertain tax positions, and tax impact of certain equity compensation.

In the normal course of business, the Company is subject to examination by taxing authorities around the world. The Company is presently under audit in select jurisdictions in the United States and in Europe, but no material impact is expected to the financial results once these audits are completed.

ASC 740 provides guidance for the accounting of uncertain income tax positions recognized in the Company's tax filings. This guidance provides that a tax benefit from an uncertain tax position may be recognized when it is more likely than not that, based on technical merits, the position will be sustained upon examination, including resolution of any related appeal or litigation process. As of September 30, 2023 and June 30, 2023, the Company’s reserve against uncertain income tax positions remained substantially unchanged at $4 million. Interest and penalties related to uncertain tax positions are recognized as a component of income tax expense.

The Company recorded a benefit for income taxes for the three months ended September 30, 2023 of $38 million relative to loss before income taxes of $797 million. The Company recorded a provision for income taxes for the three months ended September 30, 2022 of $3 million relative to earnings before income taxes of $3 million. The income tax benefit for the quarter is primarily the result of a deferred tax benefit resulting from the impairment of goodwill during the quarter and certain discrete income tax benefits. This income tax benefit was partially reduced by a $53 million valuation allowance on domestic deferred tax assets and several unfavorable permanent tax adjustments that were fixed and not impacted by the reduced pretax earnings. Discrete items recognized during the quarter include a favorable audit settlement and equity related compensation tax benefits. The quarterly provision was also impacted by the geographic distribution of the Company's pretax income resulting from our business mix, changes in the tax impact of permanent differences, restructuring, special items, certain equity related compensation, and other discrete tax items that may have unique tax implications depending on the nature of the item.
12.    EMPLOYEE RETIREMENT BENEFIT PLANS
Components of the Company’s net periodic benefit costs are as follows:
Three Months Ended  
September 30,
(Dollars in millions)20232022
Components of net periodic benefit cost:
Selling, general, and administrative expenses:
Service cost$1 $1 
Other expense, net:
Interest cost3 2 
Expected return on plan assets(2)(2)
Net amount recognized$2 $1 
As previously disclosed, the Company notified the trustees of a multi-employer pension plan of its withdrawal from participation in such plan in fiscal 2012. The actuarial review process administered by the plan trustees ended in fiscal 2015.
24

Table of Contents
The liability reported reflects the present value of the Company’s expected future long-term obligations. The estimated discounted value of the projected contributions related to such plans was $38 million as of September 30, 2023 and June 30, 2023, and is included within pension liability on the consolidated balance sheets. The annual cash impact associated with the Company’s obligations in such plan is approximately $2 million.    
13.    EQUITY AND ACCUMULATED OTHER COMPREHENSIVE LOSS
Description of Capital Stock

The Company is authorized to issue 1.00 billion shares of its Common Stock and 100 million shares of preferred stock, par value $0.01 per share. In accordance with the Company’s amended and restated certificate of incorporation, each share of Common Stock has one vote, and the Common Stock votes together as a single class.
25

Table of Contents
Accumulated Other Comprehensive Loss
The components of the changes in the cumulative translation adjustment, derivatives and hedges, and minimum pension liability for the three months ended September 30, 2023 and 2022 are presented below.
Three Months Ended  
September 30,
(Dollars in millions)20232022
Foreign currency translation adjustments:
Net investment hedge$32 $81 
Long-term intercompany loans(16)(41)
Translation adjustments(65)(160)
Total foreign currency translation adjustment, pretax(49)(120)
Tax (benefit) expense(10)15 
Total foreign currency translation adjustment, net of tax$(39)$(135)
Net change in derivatives and hedges:
Net gain recognized during the period$6 $18 
Total derivatives and hedges, pretax6 18 
Tax (benefit) expense1 4 
Net change in derivatives and hedges, net of tax$5 $14 
For the three months ended September 30, 2023 and 2022, the changes in accumulated other comprehensive loss, net of tax by component are as follows:    
(Dollars in millions)Foreign Exchange Translation AdjustmentsPension and Liability AdjustmentsDerivatives and HedgesOtherTotal
Balance at June 30, 2023$(346)$(52)$45 $(1)$(354)
Other comprehensive income (loss) before
    reclassifications
(39) 5  (34)
Net current period other comprehensive
    income (loss)
(39) 5  (34)
Balance at September 30, 2023$(385)$(52)$50 $(1)$(388)
(Dollars in millions)Foreign Exchange Translation AdjustmentsPension and Liability AdjustmentsDerivatives and HedgesMarketable SecuritiesOtherTotal
Balance at June 30, 2022$(378)$(38)$27 $(4)$(1)$(394)
Other comprehensive (loss) income before
    reclassifications
(135)— 14  — (121)
Amounts reclassified from accumulated other
    comprehensive loss
—  — — 1 
Net current period other comprehensive (loss)
    income
(135) 14 1 — (120)
Balance at September 30, 2022$(513)$(38)$41 $(3)$(1)$(514)
26

Table of Contents
14.    COMMITMENTS AND CONTINGENCIES
Litigation
From time to time, the Company may be involved in legal proceedings arising in the ordinary course of business, including, without limitation, inquiries and claims concerning environmental contamination as well as litigation and allegations in connection with acquisitions, product liability, manufacturing or packaging defects, and claims for reimbursement for the cost of lost or damaged active pharmaceutical ingredients, the cost of any of which could be significant. Such matters are inherently uncertain, and there can be no guarantee that the outcome of any such matter will be decided favorably to the Company or that the resolution of any such matter will not have a material adverse effect upon the Company’s consolidated financial statements. The Company records a liability in its consolidated financial statements for these matters when a loss is known or considered probable and the amount can be reasonably estimated. The Company reviews these estimates each accounting period as additional information is known and adjusts the loss provision when appropriate. If a matter is both probable to result in a liability and the amount of loss can be reasonably estimated, the Company estimates and discloses the possible loss or range of loss to the extent necessary for its consolidated financial statements not to be misleading. If the loss is not probable or cannot be reasonably estimated, a liability is not recorded in the Company's consolidated financial statements. Any legal or other expenses associated with the litigation are accrued for as the expenses are incurred. The Company intends to vigorously defend itself against any such litigation and does not currently believe that the outcome of any such litigation will have a material adverse effect on the Company’s consolidated financial statements. In addition, the healthcare industry is highly regulated and government agencies continue to scrutinize certain practices affecting government programs and otherwise.

City of Warwick Retirement System Class Action

In February 2023, an alleged shareholder filed a complaint styled City of Warwick Retirement System v. Catalent, Inc., et al., No. 23-cv-01108, in New Jersey federal court against the Company and three of its then-officers (collectively, “the Warwick Defendants”) purportedly on behalf of a putative “class” consisting of persons who purchased or otherwise acquired Company securities between August 30, 2021 and October 31, 2022, inclusive. On September 15, 2023, the Warwick complaint was amended (together with the original complaint, the "Warwick Complaint"), which amended complaint expanded the class period to between August 30, 2021 and May 7, 2023, inclusive (the “Class Period”). The Complaint purports to assert claims under Section 10(b) and 20(a) of the Securities Exchange Act of 1934, as amended and the related regulations, alleging that, unbeknownst to investors, Defendants purportedly engaged in accounting and channel stuffing schemes to pad Catalent’s revenues and failed to disclose adverse facts that purportedly were known to or recklessly disregarded by the Warwick Defendants. Specifically, the Warwick Complaint alleges that the Warwick Defendants (i) overstated revenue and earnings by prematurely recognizing revenue in violation of U.S. GAAP; (ii) suffered material weaknesses in its internal controls over financial reporting related to revenue recognition; (iii) falsely represented demand for its products while knowingly selling more product to its direct customers than could be sold to healthcare providers and end consumers; (iv) cut corners on safety and control procedures at key production facilities; (v) disregarded regulatory rules at key production facilities in order to rapidly produce excess inventory that was used to pad the Company’s financial results through premature revenue recognition in violation of U.S. GAAP or stuffing its direct customers with this excess inventory; and (vi) lacked a reasonable basis for their positive statements about the Company’s financial performance, outlook, and regulatory compliance during the Class Period. The Company believes that the Warwick Defendants have defenses to the allegations and claims set forth in the complaint and filed a motion to dismiss the Warwick Complaint on November 15, 2023.

Husty Derivative Claim

In August 2023, an alleged shareholder filed a derivative complaint styled Husty et al. v. Carroll, et al., No. 23-cv-00891, in Delaware federal court against certain current and former members of the Company's board of directors, (the Husty Defendants), and nominally against Catalent, Inc. The complaint mimics the allegations set out in the original complaint filed in the City of Warwick Retirement System action described above and claims that the alleged activities described there led to, and will continue to expose the Company to, costs and damages. The Company believes that the Husty Defendants have defenses to the allegations and claims set forth in the complaint and, once all Husty Defendants are properly served with the complaint, intends to vigorously defend the Husty Defendants against such allegations.

Brown Derivative Claim

In September 2023, an alleged shareholder filed a derivative complaint styled Brown, et al. v. Chiminski, et al., Case 3:23-cv-15722, in New Jersey federal court against certain current and former officers and members of the Company's board of directors (the "Brown Defendants") and nominally against Catalent, Inc. The complaint mimics the allegations set out in the original complaint filed in the City of Warwick Retirement System action described above and claims that the alleged activities
27

Table of Contents
described there led to, and will continue to expose the Company to, costs and damages. On November 8, 2023, the court entered a stipulation between the parties extending the Brown Defendants’ time to respond to the complaint until January 8, 2024. The Company believes that the Brown Defendants have defenses to the allegations and claims set forth in the complaint and intends to vigorously defend the Brown Defendants against such allegations.

Subpoenas and Requests for Information

From time to time, the Company receives subpoenas or requests for information from various governmental agencies or private parties, including from state attorneys general, the U.S. Department of Justice, and private parties. The Company generally responds to such subpoenas and requests in a timely and thorough manner, which responses sometimes require considerable time and effort and can result in considerable costs being incurred.

In June 2023, the Company received a demand from a company stockholder pursuant to 8 Del. C. § 220 to inspect books and records of the Company relating to, among other things, the allegations raised in the Warwick Complaint. The Company has responded to the demand and cannot determine at this time if the books and records demand will lead to litigation.
15.    SEGMENT INFORMATION
The Company evaluates the performance of its segments based on segment earnings before other (expense) income, impairments, restructuring costs, interest expense, income tax expense, and depreciation and amortization (“Segment EBITDA”).
Segment EBITDA is subject to important limitations. These consolidated financial statements include information concerning Segment EBITDA (a) because Segment EBITDA is an operational measure used by management in the assessment of the operating segments, the allocation of resources to the segments, and the setting of strategic goals and annual goals for the segments, and (b) in order to provide supplemental information that the Company considers relevant for the readers of the consolidated financial statements. The Company’s presentation of Segment EBITDA may not be comparable to similarly titled measures used by other companies.
The following tables include Segment EBITDA for each of the Company's current reportable segments during the three months ended September 30, 2023 and 2022:
(Dollars in millions)Three Months Ended  
September 30,
20232022
Segment EBITDA reconciled to net loss:
Biologics$49 $113 
Pharma and Consumer Health101 108 
Sub-Total$150 $221 
Reconciling items to net earnings
Unallocated costs (1)
(777)(87)
Depreciation and amortization(112)(99)
Interest expense, net(58)(32)
Income tax benefit (expense)38 (3)
Net loss$(759)$ 
(1) Unallocated costs include restructuring and special items, stock-based compensation, gain on sale of subsidiary, impairment charges, certain other corporate directed costs, and other costs that are not allocated to the segments as follows:                                                        
28

Table of Contents
(Dollars in millions)Three Months Ended  
September 30,
20232022
Impairment charges and gain/loss on sale of assets$1 $2 
Stock-based compensation (19)(19)
Restructuring and other special items(a)
(23)(9)
Goodwill impairment charges(b)
(689) 
Other expense, net(c)
(13)(25)
Unallocated corporate costs, net(34)(36)
Total unallocated costs$(777)$(87)
(a)    Restructuring and other special items during the three months ended September 30, 2023 include (i) restructuring charges associated with plans to reduce costs, consolidate facilities, and optimize our infrastructure across the organization and (ii) transaction and integration costs associated with the Metrics acquisition. For further details on restructuring charges, see Note 8, Restructuring Costs.
Restructuring and other special items during the three months ended September 30, 2022 include (i) transaction costs associated with the Metrics acquisition and (ii) warehouse exit costs for a product the Company no longer manufactures in its respiratory and specialty platform.
(b)    Goodwill impairment charges during the three months ended September 30, 2023 were associated with the Company's Consumer Health and Biomodalities reporting units, which are part of the Company's Pharma and Consumer Health and Biologics segments, respectively. For further details, see Note 4, Goodwill to the Consolidated Financial Statements.
(c)    Other expense, net during the three months ended September 30, 2023 and 2022 primarily includes foreign currency remeasurement losses/gains.

The following table includes total assets for each segment, as well as reconciling items necessary to total the amounts reported in the consolidated financial statements.
(Dollars in millions)September 30,
2023
June 30,
2023
Assets:
Biologics$5,365 $5,746 
Pharma and Consumer Health4,480 4,867 
Corporate and eliminations178 164 
Total assets$10,023 $10,777 
    
16. SUPPLEMENTAL BALANCE SHEET INFORMATION
Supplemental balance sheet information at September 30, 2023 and June 30, 2023 is detailed in the following tables.
Inventories
Work-in-process and inventories include raw materials, labor, and overhead. Total inventories consist of the following:
(Dollars in millions)September 30,
2023
June 30,
2023
Raw materials and supplies$781 $781 
Work-in-process186 186 
Total inventories, gross967 967 
Inventory cost adjustment(171)(190)
Total inventories$796 $777 
Prepaid expenses and other
29

Table of Contents
Prepaid expenses and other consist of the following:
(Dollars in millions)September 30,
2023
June 30,
2023
Prepaid expenses$63 $53 
Short-term contract assets519 399 
Spare parts supplies26 24 
Prepaid income tax89 77 
Non-U.S. value-added tax48 38 
Other current assets34 42 
Total prepaid expenses and other$779 $633 
Other accrued liabilities
Other accrued liabilities consist of the following:
(Dollars in millions)September 30,
2023
June 30,
2023
Contract liabilities$179 $167 
Accrued employee-related expenses123 160 
Accrued expenses147 134 
Operating lease liabilities11 11 
Restructuring accrual12 19 
Accrued interest27 35 
Accrued income tax44 44 
Total other accrued liabilities$543 $570 
Allowance for credit losses
The rollforward of allowance for credit losses for the three months ended September 30, 2023 is as follows:
Allowance for credit losses
(Dollars in millions) 
Balance, June 30, 2023$46 
Charges3 
Write-offs(1)
Balance, September 30, 2023$48 

17.     SUBSEQUENT EVENTS
Amendment No. 10 to Credit Agreement
On November 22, 2023, Operating Company, entered into Amendment No. 10 to Amended and Restated Credit Agreement (“Amendment No. 10”) by and among Operating Company, PTS Intermediate, the subsidiaries of Operating Company party thereto, JPMorgan Chase Bank, N.A., as the administrative agent, collateral agent, swing line lender, and letter of credit issuer, and the lenders and other parties thereto, which Amendment No. 10 further extends the deadlines by which the Operating Company is required to deliver to the Administrative Agent (i) its audited financial statements as at the end of and for the fiscal year ended June 30, 2023, together with the auditor’s report and opinion on such audited financial statements, to January 26, 2024, and (ii) its unaudited financial statements as at the end of and for the fiscal quarter ending September 30, 2023 to March 13, 2024.
Restructuring
In October 2023, and in connection with the Company's restructuring plans, the Company committed to a plan to close operations at its San Francisco facility and to transfer those operations to other sites within its network. The costs associated with this site closure are under evaluation, which may affect the amount and expected timing of costs and associated payments.
30

Table of Contents
The Company expects to incur cash and non-cash charges of at least $25 million in connection with the site closure, primarily related to accelerated depreciation of the facility in the second half of fiscal 2024. The estimated charges are subject to a number of assumptions, and actual results may differ materially from this initial estimate.
ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
The Company
We provide differentiated development and manufacturing solutions for drugs, protein-based biologics, cell and gene therapies, vaccines, and consumer health products at over fifty facilities across four continents under rigorous quality and operational standards. Our oral, injectable, and respiratory delivery technologies, along with our state-of-the-art protein, plasmid, viral, and cell and gene therapy manufacturing capacity, address a wide and growing range of modalities and therapeutic and other categories across the biopharmaceutical, pharmaceutical, and consumer health industries. Through our extensive capabilities, growth-enabling capacity, and deep expertise in product development, regulatory compliance, and clinical trial and commercial supply, we can help our customers take products to market faster, including more than half of new drug products approved by the U.S. Food and Drug Administration (the “FDA”) in the last decade. Our development and manufacturing platforms, our proven formulation, supply, and regulatory expertise, and our broad and deep development and manufacturing know-how enable our customers to advance and then bring to market more products and better treatments for patients and consumers. Our commitment to reliably supply our customers’ and their patients’ needs is the foundation for the value we provide; annually, we produce approximately 70 billion unit doses for nearly 8,000 customer prescription and consumer health products, or approximately 1 in every 26 unit doses of such products taken each year by patients and consumers around the world. We believe that, through our investments in state-of-the-art facilities and capacity expansion, including investments in facilities focused on new treatment modalities and other attractive market segments, our continuous improvement activities devoted to operational and quality excellence, the sales of existing and introduction of new customer products, and, in some cases, our innovation activities and patents, we will continue to attract premium opportunities and realize the growth potential from these areas.

Our operating structure consists of two operating and reportable segments: (i) Biologics, and (ii) Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA; iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules. Our Pharma and Consumer Health segment provides market-leading capabilities for complex oral solids, softgel formulations, Zydis fast-dissolve technologies, and gummy, soft chew, and lozenge dosage forms; formulation, development, and manufacturing platforms for oral, nasal, inhaled, and topical dose forms; cold-chain storage and distribution, and clinical trial development and supply services.

Critical Accounting Policies and Estimates
We prepare our financial statements in accordance with generally accepted accounting principles in the United States (“U.S. GAAP”). Management made certain estimates and assumptions during the preparation of the Consolidated Financial Statements in accordance with U.S. GAAP. These estimates and assumptions affect the reported amount of assets and liabilities and disclosures of contingent assets and liabilities in the consolidated financial statements. These estimates also affect the reported amount of net earnings during the reporting periods. Actual results could differ from those estimates. Because of the size of the financial statement elements to which they relate, some of our accounting policies and estimates have a more significant impact on the Consolidated Financial Statements than others.
Goodwill and Indefinite-Lived Intangible Assets
We account for purchased goodwill and intangible assets with indefinite lives in accordance with ASC 350, Intangibles – Goodwill and Other. Under ASC 350, goodwill and intangible assets with indefinite lives are not amortized, but instead are tested for impairment at least annually. We perform an impairment evaluation of goodwill annually during the fourth quarter of our fiscal year or when circumstances otherwise indicate an evaluation should be performed. The evaluation may begin with a qualitative assessment for each reporting unit to determine whether it is more likely than not that the fair value of the reporting unit is less than its carrying value. If the qualitative assessment does not generate a positive response, or if no qualitative assessment is performed, a quantitative assessment, based upon discounted cash flows, is performed and requires management to estimate future cash flows, growth rates, and economic and market conditions.

31

Table of Contents
As a result of Consumer Health's underperformance of recent operating results relative to expectations, as well as current macroeconomic conditions impacting the consumer health and biotechnology industries, and higher interest rates, we assessed the current and future economic outlook as of September 30, 2023 for our Consumer Health and Biomodalities reporting units in our Pharma and Consumer Health and Biologics segments, respectively, and identified indicators for impairment of goodwill.
The evaluation began with a qualitative assessment of each reporting unit to determine if it was more likely than not that the fair value of the reporting unit was less than its carrying value. The qualitative assessment did not indicate that it was more likely than not that the fair value exceeded the carrying value in our Consumer Health and Biomodalities reporting units, which led to a quantitative assessment for the corresponding reporting units. The evaluation performed as of September 30, 2023 resulted in a combined goodwill impairment charge of $689 million for our Consumer Health and Biomodalities reporting units within the Pharma and Consumer Health and Biologics segments, respectively.
A 50 basis point increase in the discount rate would increase the goodwill impairment $220 million and $50 million for its Biomodalities and Consumer Health reporting units, respectively. A 50 basis point decrease in the long-term growth rate would increase the goodwill impairment by $120 million and $30 million for its Biomodalities and Consumer Health reporting units, respectively.
For further details on the impairment charges for the three months ended September 30, 2023, see Note 4, Goodwill.
Other than the above, there was no material change to our critical accounting policies or in the underlying accounting assumptions and estimates from those described in our Fiscal 2023 10-K.
Non-GAAP Metrics
EBITDA from operations
Management measures operating performance based on consolidated earnings from operations before interest expense, expense for income taxes, and depreciation and amortization, adjusted for the income or loss attributable to non-controlling interests (EBITDA from operations”). EBITDA from operations is not defined under U.S. GAAP, is not a measure of operating income, operating performance, or liquidity presented in accordance with U.S. GAAP, and is subject to important limitations.
We believe that the presentation of EBITDA from operations enhances an investor’s understanding of our financial performance. We believe this measure is a useful financial metric to assess our operating performance from period to period by excluding certain items that we believe are not representative of our core business and use this measure for business planning purposes. In addition, given the significant historical investments that we have made in property, plant, and equipment, depreciation and amortization expenses represent a meaningful portion of our cost structure. We believe that EBITDA from operations will provide investors with a useful tool for assessing the comparability between periods of our ability to generate cash from operations sufficient to pay taxes, to service debt, and to undertake capital expenditures because it eliminates depreciation and amortization expense. We present EBITDA from operations in order to provide supplemental information that we consider relevant for the readers of the Consolidated Financial Statements, and such information is not meant to replace or supersede U.S. GAAP measures. Our definition of EBITDA from operations may not be the same as similarly titled measures used by other companies. The most directly comparable measure to EBITDA from operations defined under U.S. GAAP is net earnings. Included in this Management’s Discussion and Analysis is a reconciliation of net earnings to EBITDA from operations.

In addition, we evaluate the performance of our segments based on segment earnings before non-controlling interests, other expense (income), impairments, restructuring costs, interest expense, income tax expense, and depreciation and amortization (Segment EBITDA”). For a reconciliation of Segment EBITDA to net earnings, see Note 15, Segment Information to our Consolidated Financial Statements.
Use of Constant Currency
As exchange rates are an important factor in understanding period-to-period comparisons, we believe the presentation of results on a constant-currency basis in addition to reported results helps improve investors’ ability to understand our operating results and evaluate our performance in comparison to prior periods. Constant-currency information compares results between periods as if exchange rates had remained constant period-over-period. We use results on a constant-currency basis as one measure to evaluate our performance. In this Quarterly Report on Form 10-Q, we compute constant currency by calculating current period results using prior period foreign currency exchange rates. We generally refer to such amounts calculated on a constant-currency basis as excluding the impact of foreign currency exchange. These results should be considered in addition to, not as a substitute for, results reported in accordance with U.S. GAAP. Results on a constant-currency basis, as we present
32

Table of Contents
them, may not be comparable to similarly titled measures used by other companies and are not measures of performance presented in accordance with U.S. GAAP.
Other Non-GAAP Measures
Organic revenue growth and Segment EBITDA growth are measures we use to explain the underlying results and trends in the business. Organic revenue growth and Segment EBITDA growth are measures used to show current period sales and profitability from existing operations. Organic revenue growth and Segment EBITDA growth exclude the impact of foreign currency exchange, acquisitions of operating or legal entities, and divestitures within the applicable periods. These measures should be considered in addition to, not as a substitute for, performance measures reported in accordance with U.S. GAAP. These measures, as we present them, may not be comparable to similarly titled measures used by other companies and are not measures of performance presented in accordance with U.S. GAAP.
Three Months Ended September 30, 2023 Compared to the Three Months Ended September 30, 2022
The below tables summarize several financial metrics we use to measure performance for the three months ended September 30, 2023 and 2022. Refer to the discussions below regarding performance and use of key financial metrics.
5656 Gross Margin Snip.jpg

Results for the three months ended September 30, 2023 compared to the three months ended September 30, 2022 were as follows:        
 Three Months Ended  
September 30,
FX ImpactConstant Currency Increase (Decrease)
(Dollars in millions)20232022Change $Change %
Net revenue $982 $1,022 $18 $(58)(6)%
Cost of sales813 764 13 36 %
Gross margin 169 258 (94)(37)%
Selling, general, and administrative expenses 205 196 %
Goodwill impairment charges689 — — 689 *
Other operating expense, net— (1)(18)%
Operating (loss) earnings(726)60 (789)*
Interest expense, net 58 32 — 26 80 %
Other expense, net 13 25 (14)(58)%
(Loss) earnings before income taxes (797)(801)*
Income tax (benefit) expense(38)(42)*
Net loss$(759)$— $— $(759)*
* Not meaningful
33

Table of Contents
Change % calculations are based on amounts prior to rounding
Net Revenue
2023 vs. 2022
Year-Over-Year ChangeThree Months Ended  
September 30,
Net Revenue
Organic(8)%
Impact of acquisitions%
Constant-currency change(6)%
Foreign currency translation impact on reporting%
Total % change(4)%

Net revenue decreased $58 million, or 6%, excluding the impact of foreign exchange, compared to the three months ended September 30, 2022. Net revenue decreased 8% organically primarily due to a decline in demand for COVID-19 related programs, and a decline in demand for our consumer health products, primarily our wellness products, partially offset by growth from the manufacture of prescription products and our gene therapy offerings.

Net revenue increased 2% inorganically as a result of acquisitions. We acquired Metrics Contract Services (“Metrics”) in October 2022.
Gross Margin

Gross margin decreased $94 million, or 37%, compared to the three months ended September 30, 2022, excluding the impact of foreign exchange. On a constant-currency basis, gross margin, as a percentage of revenue, decreased 820 basis points to 17.0% in the three months ended September 30, 2023, compared to 25.2% in the prior-year period, primarily due to an unfavorable shift in product mix, reduced productivity, and higher costs due to increased spending on operational and engineering enhancements in our Biologics segment.
Selling, General, and Administrative Expenses

Selling, general, and administrative expenses increased $7 million, or 3%, compared to the three months ended September 30, 2022, excluding the impact of foreign exchange. The year-over-year increase was attributable to higher costs due to increased spending on operational and engineering enhancements, a one-time insurance benefit of $10 million in the prior year, $6 million in net incremental expenses from businesses acquired in the last twelve months, and $3 million of incremental credit losses.
Goodwill Impairment Charges
Goodwill impairment charges during the three months ended September 30, 2023 were associated with our Consumer Health and Biomodalities reporting units, which are part of our Pharma and Consumer Health and Biologics segments, respectively. For further details, see Note 4, Goodwill to our Consolidated Financial Statements.
Other Operating Expense, net
Other operating expense, net for the three months ended September 30, 2023 remained consistent compared to the three months ended September 30, 2022.
Interest Expense, net
Interest expense, net of $58 million for the three months ended September 30, 2023 increased $26 million, or 80%, compared to the three months ended September 30, 2022, excluding the impact of foreign exchange. The increase was primarily attributable to both a higher interest rate and increased borrowing on our revolving credit facility.

For additional information concerning our debt and financing arrangements, including the changing mix of debt and equity in our capital structure, see “—Liquidity and Capital Resources” below and Note 5, Long-Term Obligations and Short-Term Borrowings to our Consolidated Financial Statements.
Other Expense, net
34